Financial Comparison: Salix Pharmaceuticals (SLXP) & Its Competitors
Salix Pharmaceuticals (NASDAQ: SLXP) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Salix Pharmaceuticals to related businesses based on the strength of its analyst recommendations, valuation, dividends, earnings, risk, profitability and institutional ownership.
Insider & Institutional Ownership
64.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Salix Pharmaceuticals and its competitors revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Salix Pharmaceuticals Competitors||$3.02 billion||$642.98 million||-26.00|
Salix Pharmaceuticals’ competitors have higher revenue and earnings than Salix Pharmaceuticals. Salix Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Salix Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Salix Pharmaceuticals’ competitors have a beta of 1.25, indicating that their average stock price is 25% more volatile than the S&P 500.
This table compares Salix Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Salix Pharmaceuticals Competitors||-547.39%||-39.23%||-21.46%|
This is a breakdown of current ratings and recommmendations for Salix Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Salix Pharmaceuticals Competitors||69||335||989||29||2.69|
As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.85%. Given Salix Pharmaceuticals’ competitors higher probable upside, analysts clearly believe Salix Pharmaceuticals has less favorable growth aspects than its competitors.
Salix Pharmaceuticals competitors beat Salix Pharmaceuticals on 8 of the 8 factors compared.
About Salix Pharmaceuticals
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.
Receive News & Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.